Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions

Turkish Journal of Gastroenterology

Volumn 25, Issue 2, 2014, Pages 162-169

  Ince, Ali Tüzün ^a   Yildiz, Kemal ^a   Baysal, Birol ^a   Danalioǧlu, Ahmet ^a   Kocaman, Orhan ^a   Tozlu, Mukaddes ^a   Gangarapu, Venkatanarayana ^a   Kemik, Ahu Sarbay ^b   Uysal, Ömer ^a   Şentürk, Hakan ^a  

^a BEZMIALEM VAKIF UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Biliary obstruction; CA 19 9; CEA; Total antioxidant capacity; Vascular endothelial growth factor receptor 3

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; VASCULOTROPIN RECEPTOR 3; ANTIOXIDANT; TUMOR MARKER; VEGFR3 PROTEIN, HUMAN;

ADULT; ANTIOXIDANT ASSAY; ARTICLE; BILE DUCT CARCINOMA; BILE LEVEL; CHEMILUMINESCENCE IMMUNOASSAY; CHOLESTASIS; CHRONIC PANCREATITIS; COMMON BILE DUCT STONE; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; VATER PAPILLA STENOSIS; AGED; AREA UNDER THE CURVE; BILE; BILE DUCT NEOPLASMS; BLOOD; CHEMISTRY; CHOLANGIOCARCINOMA; COMPLICATION; GALLSTONES; INTRAHEPATIC BILE DUCT; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; ANTIOXIDANTS; AREA UNDER CURVE; BILE; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHOLANGIOCARCINOMA; CHOLESTASIS; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; GALLSTONES; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84905512049     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: 10.5152/tjg.2014.6056     Document Type: Article

References (54)

1. Kurt M, Onal IK, Parlak E, et al. Do metabolic alterations serve as biochemical markers in the diagnosis of malignant biliary obstruction? An observational study. Eur J Gastroenterol Hepatol 2010; 22: 58-60. [CrossRef]
2. Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994; 14: 109-14. [CrossRef] (Pubitemid 24153079)
3. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37: 806-13. [CrossRef] (Pubitemid 35404220)
4. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
5. Saluja SS, Sharma R, Pal S, Sahni P, Chattopadhyay TK. Differentiation between benign and malignant hilar obstructions using laboratory and radiological investigations: A prospective study. HPB (Oxford) 2007; 9: 373-82. [CrossRef] (Pubitemid 47604639)
6. Akdoǧan M, Parlak E, Kayhan B, Balk M, Saydam G, Sahin B. Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease? Turk J Gastroenterol 2003; 14: 181-4. (Pubitemid 37493791)
7. Konomi K, Nakamura K, Tobimatsu M, Saito S, Toyoda K, Yasunami Y. Identification of carcinoembryonic antigen (CEA) in bile of patients with malignant biliary tract disease. Jpn J Surg 1982; 12: 184-90. [CrossRef] (Pubitemid 12019869)
8. Morris-Stiff G, Teli M, Jardine N, Puntis MC. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease. Hepatobiliary Pancreat Dis Int 2009; 8: 620-6.
9. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000; 95: 204-7. [CrossRef] (Pubitemid 30041560)
10. Nichols JC, Gores GJ, LaRusso NF, Wiesner RH, Nagorney DM, Ritts RE Jr. Diagnostic role of serum CA19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 1993; 68: 874-9. [CrossRef] (Pubitemid 23266123)
11. Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. World J Gastroenterol 2004; 10: 427-32. (Pubitemid 38208101)
12. Chen CY, Shiesh SC, Tsao HC, Lin XZ. The assessment of biliary CA 125, CA19-9 and CEA in diagnosing cholangiocarcinoma - the influence of sampling time and hepatolithiasis. Hepatogastroenterology. 2002; 49: 616-20.
13. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005; 128: 1655-67. [CrossRef] (Pubitemid 40692558)
14. Mäkinen T, Veikkola T, Mustjoki S, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 2001; 20: 4762-73. [CrossRef] (Pubitemid 32848629)
15. Veikkola T, Jussila L, Makinen T, et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 2001; 20: 1223-31. [CrossRef] (Pubitemid 32233963)
16. Wong SY, Haack H, Crowley D, Barry M, Bronson RT, Hynes RO. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res 2005; 65: 9789-98. [CrossRef] (Pubitemid 41541456)
17. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 192-8. [CrossRef] (Pubitemid 32148486)
18. Inoue K, Makuuchi M, Takayama T, et al. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 2000; 127: 498-505. [CrossRef] (Pubitemid 30257507)
19. Kawarada Y, Yamagiwa K, Das BC. Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma. Am J Surg 2002; 183: 679-85. [CrossRef] (Pubitemid 34722537)
20. Cheng D, Liang B, Li Y. Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer. PLoS One 2013; 8: e55309. [CrossRef]
21. Ni XF, Wu CP, Jiang JT. Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX. World J Gastroenterol 2010; 16: 2163-9. [CrossRef]
22. Mouawad R, Spano JP, Comperat E, Capron F, Khayat D. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: Correlation with clinical parameters and outcome. Eur J Cancer 2009; 45: 1407-14. [CrossRef]
23. Benckert C, Jonas S, Cramer T, et al. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 2003; 63: 1083-92. (Pubitemid 36278442)
24. Pezzilli R, Fabbri D, Corsi MM, et al. Plasma concentrations of angiogenetic factors and angiogenetic inhibitors in patients with ductal pancreatic neoplasms. A pilot study. Clin Chem Lab Med 2011; 49: 1047-51. [CrossRef]
25. Ohira G, Kimura K, Yamada N, et al. MUC1 and HER2 might be associated with invasive phenotype of intraductal papillary mucinous neoplasm. Hepatogastroenterology 2013; 60: 1067-72.
26. Doi Y, Yashiro M, Yamada N, Amano R, Noda S, Hirakawa K. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells. Ann Surg Oncol 2012; 19: 2733-43. [CrossRef]
27. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993; 84: 407-12. (Pubitemid 23113948)
28. Ferrari CKB. Oxidative stress pathophysiology: Searching for an effective antioxidant protection. Int Med J 2001; 8: 175-84. (Pubitemid 33028907)
29. Diplock AT. Antioxidant nutrients and disease prevention: an overview. Am J Clin Nutr 1991; 53 (1 Suppl): 189S-193S.
30. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 3rd ed. UK: Oxford Science Publications; 1999.
31. Huang YL, Sheu JY, Lin TH. Association between oxidative stress and changes of trace elements in patients with breast cancer. Clin Biochem 1999; 32: 131-6. [CrossRef]
32. Liu X, Zhao J, Zheng R. DNA damage of tumor-associated lymphocytes and total antioxidant capacity in cancerous patients. Mutat Res 2003; 539: 1-8. [CrossRef] (Pubitemid 37020893)
33. Erhola M, Nieminen MM, Kellokumpu-Lehtinen P, et al. Effects of surgical removal of lung cancer on total plasma antioxidant capacity in lung cancer patients. J Exp Clin Canc Res 1998; 17: 219-25. (Pubitemid 28335582)
34. Kumaraguruparan R, Subapriya R, Kabalimoorthy J, Nagini S. Antioxidant profile in the circulation of patients with fibroadenoma and adenocarcinoma of the breast. Clin Biochem 2002; 35: 275-9. [CrossRef] (Pubitemid 34804896)
35. Sener DE, Gönenç A, Akinci M, Torun M. Lipid peroxidation and total antioxidant status in patients with breast cancer. Cell Biochem Funct 2006; 25: 377-82. [CrossRef]
36. Su H-X, Hao C-Y, Mi D-H, et al. 8-hydroxy-2′-deoxyguanosine of gastric mucosa DNA and the plasma total radical-trapping anti-oxidative capacity in patients with gastric adenocarcinoma and chronic gastritis. Chin Med J 2001; 114: 42-57.
37. Skrzydlewska E, Stankiewicz A, Sulkowska M, Sulkowski S, Kasacka I. Antioxidant status and lipid peroxidation in colorectal cancer. J Toxicol Environ Health A 2001; 64: 213-22. [CrossRef] (Pubitemid 32929955)
38. Sihvo EI, Salminen JT, Rantanen TK, et al. Oxidative stress has a role in malignant transformation in Barrett's oesophagus. Int J Cancer 2002; 102: 551-5. [CrossRef] (Pubitemid 35334460)
39. Kodydkova J, Vavrova L, Stankova B, Macasek J, Krechler T, Zak A. Antioxidant status and oxidative stress markers in pancreatic cancer and chronic pancreatitis. Pancreas 2013; 42: 614-21. [CrossRef]
40. Zhou M, Veenstra T. Mass spectrometry: m/z 1983-2008. Biotechniques 2008; 44: 667-8. [CrossRef]
41. Ali CW, Kaye TF, Adamson DJ, Tait IS, Polignano FM, Highley MS. CA19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma. J Gastrointest Cancer 2007; 38: 108-14. [CrossRef]
42. Duraker N, Hot S, Polat Y, Höbek A, Gençler N, Urhan N. CEA, CA19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 2007; 95: 142-7. [CrossRef] (Pubitemid 46238983)
43. Marrelli D, Caruso S, Pedrazzani C, et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg 2009; 198: 333-9. [CrossRef]
44. Torzilli G, Makuuchi M, Ferrero A, et al. Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients. Hepatogastroenterology 2002; 49: 740-5. (Pubitemid 34615340)
45. Nakeeb A, Lipsett PA, Lillemoe KD, et al. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am J Surg 1996; 171: 147-52. [CrossRef] (Pubitemid 126349889)
46. Juntermanns B, Radunz S, Heuer M, et al. Tumor markers as a diagnostic key for hilar cholangiocarcinoma. Eur J Med Res 2010; 15: 357-61. [CrossRef]
47. Maxwell P1, Davis RI, Sloan JM. Carcinoembryonic antigen (CEA) in benign and malignant epithelium of the gall bladder, extrahepatic bile ducts, and ampulla of Vater. J Pathol 1993; 170: 73-6. [CrossRef]
48. Bätge B, Bosslet K, Sedlacek HH, Kern HF, Klöppel G. Monoclonal antibodies against CEA-related components discriminate between pancreatic duct type carcinomas and nonneoplastic duct lesions as well as nonduct type neoplasias. Virchows Arch A Pathol Anat Histopathol 1986; 408: 361-74. [CrossRef]
49. Han FH, Li HM, Zheng DH, He YL, Zhan WH. The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol 2010; 36: 1172-9. [CrossRef]
50. Witte D, Thomas A, Ali N, Carlson N, Younes M. Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res 2002; 22: 1463-6. (Pubitemid 34839151)
51. Shukla VK, Adukia TK, Singh SP, Mishra CP, Mishra RN. Micronutrients, antioxidants, and carcinoma of the gallbladder. J Surg Oncol 2003; 84: 31-5. [CrossRef] (Pubitemid 37075692)
52. Elsing C, Voss A, Herrmann T, Kaiser I, Huebner CA, Schlenker T. Oxidative stress reduces Na+/H+ exchange (NHE) activity in a biliary epithelial cancer cell line (Mz-Cha-1). Anticancer Res 2011; 31: 459-65.
53. Jaiswal M, LaRusso NF, Shapiro RA, Billiar TR, Gores GJ. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology. 2001; 120: 190-9. [CrossRef] (Pubitemid 32061883)
54. Pastor A, Collado PS, Almar M, González-Gallego J. Antioxidant enzyme status in biliary obstructed rats: effects of N-acetylcysteine. J Hepatol 1997; 27: 363-70. [CrossRef] (Pubitemid 27366218)